Founded to serve health, Servier is a global group governed by a Foundation that aspires to have a meaningful social impact, both for patients and for a sustainable world. With its unique governance model, it can fully serve its vocation with a long-term vision: being committed to therapeutic progress to serve patient needs. The 21,400 employees of the Group are committed to this shared vocation, source of inspiration every day.
As a world leader in cardiology, Servier's ambition is to become a focused and innovative player in oncology by targeting hard-to-treat cancers. That is why the Group allocates over 50% of its R&D budget to developing targeted and innovative therapies in oncology.
Neuroscience and immuno-inflammatory diseases are the future growth drivers. In these areas, Servier is focused on a limited number of diseases in which accurate patient profiling makes it possible to offer a targeted therapeutic response through precision medicine.
To promote access to quality care for all at a lower cost, the Group also offers a range of quality generic drugs covering most pathologies, relying on strong brands in France, Eastern Europe, Brazil and Nigeria.
In all these areas, the Group includes the patient voice at each stage of the life cycle of a medicine.
Headquartered in France, Servier relies on a strong geographical footprint in over 150 countries and achieved a revenue of €4.9 billion in 2022.
--
To report a suspected adverse event with a Servier drug, please visit servier.com
|
|
|
|
|
10,001+ employees
View all Servier employees
|
|
|
Pharmaceuticals
|
|
|
50 rue Carnot, Suresnes, FR
|
|
|
1954
|
|
|
As Well As For Diabetes And Clinical Depression, Medication For Cardiological And Rheumatological Conditions
|
Anna Hill is the CEO of Servier. To contact Anna Hill email at [email protected].
The decision makers in Servier are Brad Lloyd, Florent Darchez, Horace Mccoy, etc. Click to Find Servier decision makers emails.
Servier specializes in a range of medical conditions, including cardiological issues, rheumatological conditions, diabetes, and clinical depression. The company is dedicated to developing innovative treatments that improve patient outcomes and enhance quality of life.
Servier is committed to sustainability and social responsibility. The company operates under a foundation that prioritizes meaningful social impact, focusing on initiatives that promote health equity, environmental sustainability, and access to essential medications for underserved populations.
Servier invests heavily in research and development to discover and develop new therapies. The company collaborates with academic institutions, healthcare professionals, and other organizations to advance scientific knowledge and bring innovative solutions to market, particularly in the fields of cardiology, diabetes, and mental health.
Yes, Servier provides various patient support programs aimed at helping individuals manage their conditions effectively. These programs may include educational resources, access to healthcare professionals, and tools to assist with medication adherence and lifestyle changes.
Servier operates in numerous countries around the world, with a strong presence in Europe, Asia, and Africa. The company is dedicated to expanding its reach to ensure that patients globally have access to its innovative treatments and healthcare solutions.
Healthcare professionals interested in collaborating with Servier can reach out through the company's official website or contact their local Servier representative. The company values partnerships that enhance research, clinical trials, and the development of new therapies to improve patient care.
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 350M professionals from 40M companies with the right contact details.